Table 2 Coadjuvant therapy
From: Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial
Treatment | Sildenafil group (n = 20) | Placebo group (n = 20) | Total (n = 40) | |
|---|---|---|---|---|
Dexamethasone (n, %) | 17 (86%) | 16 (80%) | 33 (82.5%) | |
Azithromycin (n, %) | 4 (20%) | 4 (20%) | 8 (20%) | |
Ceftriaxone (n, %) | 16 (80%) | 14 (70%) | 30 (75%) | |
Therapeutic anticoagulation (n, %) | 2 (10%) | 3 (15%) | 5 (12.5%) |